• Teva Page Title

Korporativne novice

Opomba: novice so v angleškem jeziku, povezave vodijo na korporativno stran podjetja Teva.

18.09.2018

Teva Announces Early Results of Debt Tender Offer and Election of Early Settlement

JERUSALEM--(BUSINESS WIRE)--Sep. 18, 2018-- Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) announced today the early tender results in connection with its previously announced tender offers (the “Offers”) to purchase for cash for a combined aggregate purchase price (exclusive of accrued and unpaid interest) of up to $400 million (the “Maximum Amount”) a portion of the following series of notes issued by finance subsidiaries of Teva and guaranteed by Teva: 1.700% Senior Notes due 2019, CUSIP 88167A AB7 / ISIN US88167AAB70, issued by Teva Pharmaceutical Finance Netherlands III B.V. (the “Priority 1 No...
15.09.2018

Teva Announces U.S. Approval of AJOVY™ (fremanezumab-vfrm) Injection, the First and Only Anti-CGRP Treatment with Both Quarterly and Monthly Dosing for the Preventive Treatment of Migraine in Adults

JERUSALEM--(BUSINESS WIRE)--Sep. 14, 2018-- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that the U.S. Food and Drug Administration (FDA) has approved AJOVYTM (fremanezumab-vfrm) injection for the preventive treatment of migraine in adults. AJOVY, a humanized monoclonal antibody that binds to calcitonin gene-related peptide (CGRP) ligand and blocks its binding to the receptor, is the first and only anti-CGRP treatment for the prevention of migraine with quarterly (675 mg) and monthly (225 mg) dosing options. This press release features multimedia. View the full release here: https://www.businesswir...
12.09.2018

Teva to Present at the Morgan Stanley Global Healthcare Conference

JERUSALEM--(BUSINESS WIRE)--Sep. 12, 2018-- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) will host a live audio webcast at the Morgan Stanley Global Healthcare Conference in New York, NY. What: Teva Presentation at the Morgan Stanley Global Healthcare Conference in New York, NY. Who: Michael McClellan, Chief Financial Officer When: Friday, September 14, 2018 at 9:20am (ET) Where: Teva's Investor Relations website at ir.tevapharm.com. The webcast can also be accessed through the following URL: https://cc.talkpoint.com/morg007/091218a_as/?entity=140_5NHE0JF How: Register f...
04.09.2018

Teva Announces $400 Million Debt Tender Offer

JERUSALEM--(BUSINESS WIRE)--Sep. 4, 2018-- Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) announced today that it has commenced tender offers (the “Offers”) to purchase for cash for a combined aggregate purchase price (exclusive of accrued and unpaid interest) of up to $400 million (the “Maximum Amount”) of the following series of notes issued by finance subsidiaries of Teva and guaranteed by Teva: 1.700% Senior Notes due 2019, CUSIP 88167A AB7 / ISIN US88167AAB70, issued by Teva Pharmaceutical Finance Netherlands III B.V. (the “Priority 1 Notes”); 0.375% Senior Notes due 2020, ISI...
16.08.2018

Teva and Regeneron Announce Positive Topline Phase 3 Fasinumab Results in Patients with Chronic Pain from Osteoarthritis of the Knee or Hip

Data include final primary efficacy results and an interim safety analysis JERUSALEM & TARRYTOWN, N.Y.--(BUSINESS WIRE)--Aug. 16, 2018-- Teva Pharmaceutical Industries Ltd. (NYSE and TASE:TEVA) and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced positive topline results from a Phase 3, randomized, double-blind, placebo-controlled study of fasinumab in patients with chronic pain from osteoarthritis (OA) of the knee or hip. At the week 16 primary efficacy analysis, the study met both co-primary endpoints and all key secondary endpoints. Fasinumab-treated patients experienced significantly less pain and sig...
06.08.2018

Teva Announces Updated Indication and Vial Presentation for GRANIX® (tbo-filgrastim) Injection in United States

JERUSALEM--(BUSINESS WIRE)--Aug. 6, 2018-- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that the U.S. Food and Drug Administration (FDA) has approved GRANIX® (tbo-filgrastim) Injection for a new vial presentation and indication in pediatric patients 1 month and older. GRANIX is indicated to reduce the duration of severe neutropenia in adult and pediatric patients 1 month and older with nonmyeloid malignancies receiving myelosuppressive anticancer drugs associated with a clinically significant incidence of febrile neutropenia. The new vial presentation of the product will be available for use i...
02.08.2018

Teva Reports Second Quarter 2018 Financial Results

Revenues of $4.7 billion Free cash flow of $0.6 billion GAAP diluted loss per share of $0.24 Non-GAAP diluted EPS of $0.78 Restructuring plan on-track to achieve $1.5 billion of savings in 2018 and in total $3.0 billion by the end of 2019 Raising 2018 full year guidance: Non-GAAP EPS guidance raised to $2.55-2.80 from $2.40-$2.65 Free cash flow guidance raised to $3.2-3.4 billion from $3.0-3.2 billion JERUSALEM--(BUSINESS WIRE)--Aug. 2, 2018-- Teva Pharmaceutical Industries Lt...
17.07.2018

Teva Highlights Key Milestones Achieved in the 2017 Social Impact Report

JERUSALEM--(BUSINESS WIRE)--Jul. 17, 2018-- Today, Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) published its annual social impact report, highlighting achievements related to the two pillars that drive the Company’s initiatives: building healthy communities and leading a responsible business. Teva’s 2017 Social Impact Report spotlights the company’s commitment to corporate responsibility and transparency, and provides context on its efforts to contribute to healthy communities in ways the business can uniquely support—through safe medicines, collaboration, health initiatives and innovative research. The repo...
11.07.2018

Teva to Report Second Quarter 2018 Financial Results on August 2, 2018

JERUSALEM--(BUSINESS WIRE)--Jul. 11, 2018-- Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) announced today that it will release its second quarter 2018 financial results on Thursday, August 2, 2018 at 7:00 a.m. ET. Teva will host a conference call and live webcast on the same day, at 8:00 a.m. ET to discuss its second quarter 2018 results and overall business environment. A Question & Answer session will follow this discussion. In order to participate, please dial the following numbers (at least 10 minutes before the scheduled start time): United States ...
09.07.2018

Teva Announces Launch of a Generic Version of Uceris® in the United States

JERUSALEM--(BUSINESS WIRE)--Jul. 9, 2018-- Teva Pharmaceutical Industries Ltd., (NYSE and TASE: TEVA) today announced the launch of a generic version of Uceris®1 (budesonide) extended-release tablets, 9 mg, in the U.S. Budesonide extended-release tablets are a glucocorticosteroid indicated for the induction of remission in patients with active, mild to moderate ulcerative colitis. “The launch of generic budesonide extended-release tablets signals an important addition to Teva’s portfolio,” said Brendan O’Grady, EVP and head of North America Commercial. “We continue to be focused on bringing affordable gener...